{"id":"ampiroxicam","rwe":[{"pmid":"38974039","year":"2024","title":"Exploring the pharmacokinetics and tolerability of cyclooxygenase inhibitor ampiroxicam: a phase I study on single and multiple oral doses.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"25041257","year":"2014","title":"Risk factors of symptomatic NSAID-induced small intestinal injury and diaphragm disease.","finding":"","journal":"Alimentary pharmacology & therapeutics","studyType":"Clinical Study"},{"pmid":"23273940","year":"2013","title":"Simultaneous determination for oxicam non-steroidal anti-inflammatory drugs in human serum by liquid chromatography-tandem mass spectrometry.","finding":"","journal":"Forensic science international","studyType":"Clinical Study"},{"pmid":"22182582","year":"2012","title":"Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"21496182","year":"2011","title":"Inhibition of myeloid cell leukemia-1 by tolfenamic acid induces apoptosis in mucoepidermoid carcinoma.","finding":"","journal":"Oral diseases","studyType":"Clinical Study"}],"tags":[{"label":"Nonsteroidal Anti-inflammatory Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Cyclooxygenase Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":["NCT00086580"],"aliases":[],"patents":[],"pricing":[],"allNames":"flucam","offLabel":[],"synonyms":["flucam","ampiroxicam","CP-65703","CP 65703"],"timeline":[],"brandName":"Flucam","ecosystem":[],"mechanism":{"moaClass":"Cyclooxygenase Inhibitors","modality":"Small Molecule","drugClass":"Nonsteroidal Anti-inflammatory Drug","explanation":"Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. Flucam blocks these messengers from being made, which helps to reduce pain and inflammation. This is similar to how other NSAIDs, like ibuprofen, work.","oneSentence":"Flucam works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins that cause pain and inflammation.","technicalDetail":"Flucam is a competitive inhibitor of COX-1 and COX-2 enzymes, which are responsible for the conversion of arachidonic acid to prostaglandin H2, a precursor to various prostaglandins involved in pain and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/199","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPIROXICAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:18.276423","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ampiroxicam","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00086580","phase":"Phase 3","title":"A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":true,"enrollment":335,"indication":"B-Cell Chronic Lymphocytic Leukemia","completionDate":"2010-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"MMSL":"1529","NDDF":"002389","UNII":"0PV32JZB1J","CHEBI":"CHEBI:31210","VANDF":"4018626","INN_ID":"6047","RXNORM":"8356","UMLSCUI":"C0246289","ChEMBL_ID":"CHEMBL1566249","KEGG_DRUG":"D01397","DRUGBANK_ID":"DB16877","PUBCHEM_CID":"2176","SNOMEDCT_US":"27754002","MESH_DESCRIPTOR_UI":"D010894","MESH_SUPPLEMENTAL_RECORD_UI":"C065946"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"0%"},"publicationCount":19,"therapeuticAreas":["Pain"],"biosimilarFilings":[],"recentPublications":[{"date":"2024","pmid":"38974039","title":"Exploring the pharmacokinetics and tolerability of cyclooxygenase inhibitor ampiroxicam: a phase I study on single and multiple oral doses.","journal":"Frontiers in pharmacology"},{"date":"2014 Sep","pmid":"25041257","title":"Risk factors of symptomatic NSAID-induced small intestinal injury and diaphragm disease.","journal":"Alimentary pharmacology & therapeutics"},{"date":"2013 Apr 10","pmid":"23273940","title":"Simultaneous determination for oxicam non-steroidal anti-inflammatory drugs in human serum by liquid chromatography-tandem mass spectrometry.","journal":"Forensic science international"},{"date":"2012 Feb 15","pmid":"22182582","title":"Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity.","journal":"European journal of pharmacology"},{"date":"2011 Jul","pmid":"21496182","title":"Inhibition of myeloid cell leukemia-1 by tolfenamic acid induces apoptosis in mucoepidermoid carcinoma.","journal":"Oral diseases"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flucam is a small molecule. It has been studied in combination with Fludara and Campath for the treatment of B-Cell Chronic Lymphocytic Leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}